Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegfilgrastim biosimilar - CSPC Pharma

Drug Profile

Pegfilgrastim biosimilar - CSPC Pharma

Alternative Names: Jinyouli; PEG-rhG-CSF - CSPC Pharma; Pegylated filgrastim - CSPC Pharma

Latest Information Update: 25 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC Pharma
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 05 Aug 2020 CSPC Baike (Shandong) Biopharmaceutical plans a clinical trial in Neutropenia (Chemotherapy-induced, Prevention) in China (SC, Injection) (NCT04500886)
  • 04 Aug 2020 CSPC Baike (Shandong) Biopharmaceutical plans a clinical trial for Infections (Prevention, In neonates, In infants, In children, In adolescents) (in haematological malignancies) in China (SC) (NCT04497701)
  • 23 Jan 2020 CSPC Baike initiates enrolment in a clinical trial for Neutropenia (Chemotherapy induced, Prevention) in China (SC) (NCT04239001)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top